The Australian pharmaceutical company Antisense Therapeutics Limited announced that they have recruited 24 patients into a trial for the acromegaly drug ATL 1103, and have completed the dosing regimen with two-thirds of the recruits. Thus far the company reports "positive" interim data for the injectable drug that aims to reduce levels of insulin-like growth factor 1 (IGF-1) in the blood. The results of the second phase will be reported this summer. Read more here.